Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlormidazole→

Chlormidazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3689-76-7
Molecular formula
C15H13ClN2
Molecular weight
256.73 g/mol
Drug class
Topical benzimidazole antifungalearly azole antimycotic
Mechanism of action
An early benzimidazole azole antifungal. The azole class inhibits fungal lanosterol 14-alpha-demethylase (CYP51), impairing ergosterol biosynthesis and compromising fungal cell-membrane integrity. The exact enzyme target was not established in the original chlormidazole development studies.
Indications / reported uses
  • Historically marketed as 5% topical cream or tincture for dermatomycoses and Candida infections; products appear to have been withdrawn or are no longer widely available. This is a historical pharmacology entry, not a current routine treatment.
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Chlormidazole Environmental Risk Assessment (ERA) (the Chlormidazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.